Introduction
Triazolopyrimidines represent a pharmaceutically important class of compounds because of their diverse range of biological activities, such as antitumor [1] , cytotoxicity [2] , therapeutic potentiality [3] , potent and selective ATP site directed inhibition of the EGF-receptor protein tyrosine kinase [4] and cardiovascular [5] activities. In addition, they have been found in DNA-interactive drugs [6] and as useful building blocks in the synthesis of herbicidal drugs, e.g. Metosulam, Flumetsulam, Azafenidin, Diclosulam, Penoxsulam, Floransulan, Cloransulam etc. Also, various derivatives of 1,2,4-triazolo [4,3-a] pyrimidine were reported to be useful as calcium-channelblocking vasodilators, some have antihypertensive [7] , cardiovascular [8, 9] and anxiolytic [10] activities.
In view of these reports and in continuation of our interest in the synthesis of a variety of heterocyclic systems for biological evaluation [11] [12] [13] [14] [15] [16] [17] , we describe herein a facile synthesis of some new 1,2,4-triazolo [5,1-a] pyrimidine derivatives and study the anti-carcinogenic effects of two newly synthesized derivatives, 7,8-dihydro-6H-cyclopenta[e] [1, 2, 4] triazolo [1,5-a] pyrimidine and 6,7,8,9,10,11-hexahydrocyclo octa[e] [1, 2, 4] triazolo [1,5-a] pyrimidine against human hepatocarcinoma (HepG2) and breast carcinoma (MCF7).
Experimental

Synthesis
All melting points were determined on an Electrothermal apparatus and are uncorrected. IR spectra were recorded (KBr discs) on a Shimadzu FT-IR 8201 PC spectrophotometer. 1 H NMR and 13 C NMR spectra were recorded in CDCl3 on a Varian mercury VXR-300 (300 MHz for 1 H and 75 MHz for 13 C). Chemical shifts are expressed in  ppm units using TMS as an internal reference. Mass spectra were recorded on a GC-MS QP1000 EX Shimadzu. Elemental analyses were carried out at the Micro analytical Center of Cairo University.
Sodium (E)-(2-oxocycloalkylidine)-methanolates (2a-d)
In a three necked flask containing sodium methoxide (5.4 g, 0.01 mol), and diethyl ether (20 mL), the appropriate cyclopentanone, cyclohexanone, cycloheptanone or cyclooctanone (0.01) mol with ethyl formate (7.5 g, 0.01 mol) was poured over it through separating funnel with efficient stirring. The solid formed was collected and used directly in the reactions [13] .
Scheme 1
[1,2,4]triazolo[1,5-a]pyrimidine derivatives (6a-d)
Method A: A mixture of the appropriate 2a-d (5 mmol), 1H-1,2,4-triazol-5-amine 5 (0.42 g, 5 mmol) and few drops of acetic acid was thoroughly ground with pestle in an open mortar at room temperature for 3-5 min until the mixture turned into a melt. Grinding of the initial syrupy continued for 5-7 min and the progress of the reaction was monitored by TLC. The remaining solid was filtered, washed with water and recrystallized from chloroform gave the corresponding fused pyrimidines 6a-d, respectively.
Method B: A solution of the appropriate of compound 2a-d (5 mmol), 1H-1,2,4-triazol-5-amine 5 (0.42 g, 5 mmol)) and piperidinium acetate (1 mL) in H2O (3 mL) was refluxed for 15 min. Acetic acid (1 mL) was added to the hot solution. The solid product was filtered off and recrystallized from chloroform gave product identical in all aspects (m.p. and spectra) with 6a-d (Scheme 1). 
Pharmacology
Materials and methods
Human tumor cell lines
Human hepatocarcinoma cell lines (HepG2) and breast carcinoma cell lines (MCF7) used in this study were obtained from the American Type Culture Collection (ATCC, Minisota, U.S.A.). The tumor cell lines were maintained at the National Cancer Institute, Cairo, Egypt, by serial sub-culturing.
Preparation of the tested compounds
The two derivatives, 
Preparation of culture medium
RPMI-1640 medium was used for culturing and maintenance of the human tumor cell lines. The medium was supplied in a powder form. The working solution was prepared by dissolving 10.4 g powder and 2 g sodium bicarbonate dissolved in 1 L distilled water. The medium was then sterilized by filtration in a Millipore bacterial filter (0.22 μm). The prepared medium was kept in a refrigerator (4 °C). Before use, the medium was warmed at 37 °C in a water bath and the supplemented with 1% penicillin/(2 mg/mL) streptomycin and 10% fetal bovine serum.
Procedures
Maintenance of the human cancer cell lines in the laboratory
A cryotube containing frozen cells was taken out of the liquid nitrogen container and then thawed in a water bath at 37 °C. The cryotube was opened under strict aseptic conditions and its contents were supplied by 5 mL supplemented medium drop by drop in a 50 mL sterile falcon tubes. The tube was incubated for 2 hours then centrifuged at 1200 rpm for 10 min and the supernatant was discarded. The supernatant was discarded and the cell pellet was suspended and seeded in 5 mL supplemented medium in T25 Nunclon sterile tissue culture flasks. The cell suspension was incubated and followed up daily the supplemented medium was replaced every 2-3 days. Incubation was continued until a confluent growth was achieved and the cells were freshly sub cultured before each experiment to be in the exponential phase of growth.
Collection of cells by trypsinization
The medium was discarded. The monolayer cell was washed twice with 5 ml phosphate buffered saline. All the adherent cells were dispersed from their monolayer by the addition of 1 mL trypsin solution (0.25 % trypsin, w:v) for 2 minutes.
Determination and counting of viable cells
50 μL of 0.05 % trypan blue solution was added to 50 μL of the single cell suspension. The cells were examined under the inverted microscope using the haemocytometer. Non stained (viable) cells were counted and the following equation was used to calculate the cell count/mL of cell suspension.
Viable cells/mL = number of cells in 4 quarters x 2 (dilution factor) x 10 4 / 4
The cells were then diluted to give the required cell number for each experiment.
Cryopreservation of cells
To avoid the loss of the cell line, excess cells were preserved in liquid nitrogen. Equal parts of the cell suspension and freezing medium (10 % DMSO in supplemented medium) were dispersed to cryotubes. The cryotubes were racked in appropriately labeled polystyrene boxes, gradually cooled till reaching -80 °C. Then the cryotubes were stored in liquid nitrogen (-180 °C) till use.
Determination of potential cytotoxicity of drug on human cancer cell line
The cytotoxicity was carried out using sulphorhodamine-B (SRB) assay following the method reported by Vichai and Kirtikara [13] and Hussein and Ahmed [14, 15] . SRB is a bright pink aminoxanthrene dye with two sulphonic groups. It is a protein stain that binds to the amino groups of intracellular proteins under mildly acidic conditions to provide a sensitive index of cellular protein content.
Cells were maintained in RPMI-1640 medium with 10% foetal calf serum, sodium pyruvate, 100 U/mL penicillin and 2 mg/mL streptomycin at 37 °C and 5% CO2. Cells were seeded in 96-well micro titer plates at initial concentration of 3×10 3 cell/well in a 150 µL fresh medium and left for 24 hours to attach to the plates. Different concentrations 0, 5, 12.5, 25, and 50 µg/mL of the tested compounds were added. For each concentration, 3 wells were used. The plates were incubated for 48 hours. The cells were fixed with 50 μL cold trichloroacetic acid 10% final concentration for 1 hour at 4 °C. The plates were washed with distilled water using (automatic washer Tecan, Germany) and stained with 50 μL 0.4 % SRB dissolved in 1 % acetic acid for 30 minutes at room temperature. The plates were washed with 1 % acetic acid and air-dried. The dye was solubilized with 100 μL/well of 10 M tris base (pH = 10. 
Results and discussion
Synthesis
Treatment of 1H-1,2,4-triazol-5-amine (5) with sodium (E)-(2-oxocyclooctylidene)methanolate (2d) in acetic acid containing piperidinium acetate afforded a product namely 6,7,8,9,10,11-hexahydrocycloocta[e][1,2,4]triazolo[1,5-a] pyrimidine (9d) (Scheme 1). The structure was confirmed by elemental analysis, spectral data and X-ray single crystal diffraction data (Figure 1) (Table 1 and 2). The reaction seemed to be via the initial nucleophilic attack by the exocyclic amino group at the formyl group 4, which formed in situ from compound 2d with water, followed by cyclization and elimination of one molecule of water leading to the formation of the product 6d (Scheme 1). 
Cytotoxicity against different human cancer cell lines in vitro
Many triazolopyrimidine derivatives were previously reported to have anti-tumour effects [17] . Navarro [1] found that 4,7-H-5-methyl-7-oxo [1, 2, 4] triazolo [1,5-a] pyrimidine have a moderate antitumor activity against breast carcinoma, MCF7 cell lines. (Figure 2 and 3) .
Similar to the effect on HepG2, the two tested triazolopyrimidine derivatives had potential cytotoxic effects on breast carcinoma cell lines (MCF7). The survival fraction was gradually and sharply decreased as the concentration of the tested derivatives was increased from 5 to 25 µg/mL. As the concentration in the culture media was increased from 25 to 50 µg/mL, the cytotoxic effects were more or less not progressed. The IC50 of 6,7,8,9,10,11-hexahydrocycloocta 
Conclusion
Synthesis of new [1, 2, 4] triazolo[1,5-a]pyrimidine derivatives was accomplished and structures were elucidated by means of various characterization techniques such as elemental analyses, spectral (IR, 1 H NMR, 13 C NMR, 2D NMR), and X-ray single crystal diffraction data. These derivatives were evaluate for in vitro anti-tumor using various human cancer cell lines
